New LEADER trial analysis shows reduction in cardiovascular risk in people with type 2 diabetes

New findings from a post-hoc analysis of the LEADER cardiovascular (CV) outcomes trial were presented recently at the 77th annual Scientific Sessions of the American Diabetes Association (ADA). The findings showed that treatment with liraglutide (Victoza) 1.8mg once daily, resulted in similar reductions in the risk of major CV events in adults with type 2 diabetes  at high CV risk, regardless of whether or not they experienced an episode of severe hypoglycaemia during the trial. For the overall LEADER population, regardless of treatment group, people who experienced a severe hypoglycaemic episode were at a significantly greater risk of major cardiovascular adverse events